Drugs / SL-172154
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05483933 | Aug 2022 → Feb 2025 | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma, refractory malignant neoplasm | Shattuck Labs, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05275439 | Mar 2022 → Feb 2025 | acute myeloid leukemia, myelodysplastic syndrome | Shattuck Labs, Inc. | Terminated | Missed primary |
| Phase 1 | NCT04502888 | Sep 2020 → Apr 2022 | head and neck squamous cell carcinoma, skin squamous cell carcinoma | Shattuck Labs, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04406623 | Jun 2020 → Feb 2023 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Shattuck Labs, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2024-10-01 | Shattuck Labs, Inc. | Results Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway shattucklabs.com ↗
Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement in median overall survival compared to azacitidine monotherapy benchmarks; further development of SL-172154 discontinued |
| 2024-08-01 | Shattuck Labs, Inc. | Results Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights shattucklabs.com ↗
SL-172154 demonstrated a manageable interim safety profile in combination with AZA. |
| 2024-06-14 | Shattuck Labs, Inc. | Results Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients shattucklabs.com ↗
Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a potential new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced updated interim data from the Phase 1B dose expansion clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. |
| 2024-06-10 | Shattuck Labs, Inc. | Regulatory Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) shattucklabs.com ↗
Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that the U.S. FDA has granted orphan drug designation (ODD) to lead clinical candidate SL-172154 for the treatment of AML. |
| 2024-05-14 | Shattuck Labs, Inc. | Results Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress shattucklabs.com ↗
The complete response rate in HR-MDS increased by the February 1 st data cutoff, and the ORR increased in the TP53m AML cohort. |
| 2023-12-13 | Shattuck Labs, Inc. | Results Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients shattucklabs.com ↗
today announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. |
| 2023-11-02 | Shattuck Labs, Inc. | Results Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual Meeting shattucklabs.com ↗
We were particularly pleased to observe initial anti-leukemic activity, unique pharmacodynamic activity, and an acceptable safety and tolerability profile for SL-172154 as monotherapy and in combination with azacitidine. |
| 2023-05-25 | Shattuck Labs, Inc. | Results Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting shattucklabs.com ↗
In the Phase 1A dose-escalation trial, SL-172154 had maximal CD47 and CD40 target engagement and CD40-dependent pharmacodynamic effects observed at the 3 mg/kg dose. |
| 2021-11-09 | Shattuck Labs, Inc. | Results Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights shattucklabs.com ↗
SL-172154 (SIRPα-Fc-CD40L) demonstrates high levels of CD47 target occupancy and evidence of dose-dependent CD40-mediated immune activation |
| 2021-11-09 | Shattuck Labs, Inc. | Results Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252 shattucklabs.com ↗
For SL-172154 (SIRPα-Fc-CD40L), initial monotherapy Phase 1 dose-escalation data show favorable safety and tolerability for a CD40 agonist, high levels of CD47 target occupancy and CD40 target engagement, and escalating pharmacodynamic activity in heavily pretreated, platinum resistant ovarian cancer patients. |
| 2021-08-11 | Shattuck Labs, Inc. | Results Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252 shattucklabs.com ↗
Reported initial safety data from SL-172154 (SIRPα-Fc-CD40L) Phase 1 trial in ovarian cancer suggesting an encouraging early safety profile and ability to dose escalate beyond prior CD40 agonist antibodies |
All press releases naming this drug 14 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SL-172154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05483933 ↗ |
| Known as | SIRPα-Fc-CD40L | “SL-172154 (SIRPα-Fc-CD40L)” NCT05483933 ↗ |
| Action | Activate | “Agonist Redirected Checkpoint” NCT04502888 ↗ |
| Modality | Protein / enzyme biologic | “SL-172154 is a hexameric fusion protein adjoining the extracellular domain of SIRPα to the extracellular domain of CD40L via an inert IgG4-derived Fc domain.” PMID 39800375 ↗ Jan 2025 |
| Route | Intravenous | “SL-172154 was administered intravenously at 0.1, 0.3, 1.0, 3.0, and 10.0 mg/kg.” PMID 39800375 ↗ Jan 2025 |
| Target | CD40 | “First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.” PMID 39800375 ↗ Jan 2025 |
| Target | CD47 | “First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.” PMID 39800375 ↗ Jan 2025 |